NASDAQ:SLDB Solid Biosciences Q2 2026 Earnings Report $8.02 -0.90 (-10.09%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$8.07 +0.05 (+0.61%) As of 07:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Solid Biosciences EPS ResultsActual EPS-$0.38Consensus EPS -$0.46Beat/MissBeat by +$0.08One Year Ago EPSN/ASolid Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASolid Biosciences Announcement DetailsQuarterQ2 2026Date8/6/2026TimeAfter Market ClosesConference Call DateThursday, August 6, 2026Conference Call Time7:00AM ETUpcoming EarningsSolid Biosciences' Q3 2026 earnings is estimated for Monday, November 2, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Solid Biosciences Earnings HeadlinesSolid Biosciences (NASDAQ:SLDB) Earns Outperform Rating from Analysts at Royal Bank Of CanadaSeptember 19, 2026 | americanbankingnews.comRBC Capital initiates coverage of Solid Biosciences at outperformSeptember 17, 2026 | msn.comHas Dylan Jovine lost his mind?SpaceX just signed a deal JPMorgan says could unlock the next phase of the space economy, putting the company on a path toward a 10 trillion valuation. But analyst Dylan Jovine says the biggest winner won't be SpaceX itself. He's identified a small firm, less than half a percent SpaceX's size, that partnered with it directly. An upcoming NASA announcement could be the catalyst. Jovine previously flagged Rocket Lab before it climbed from under 4 dollars to over 151.September 24 at 1:00 AM | Behind the Markets (Ad)Solid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC SaysSeptember 16, 2026 | finance.yahoo.comSolid Biosciences wins new Outperform at RBC on DMD opportunitySeptember 16, 2026 | seekingalpha.comSolid Biosciences (SLDB) Gets a Buy from CitiSeptember 12, 2026 | theglobeandmail.comSee More Solid Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Solid Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Solid Biosciences and other key companies, straight to your email. Email Address About Solid BiosciencesSolid Biosciences (NASDAQ:SLDB) (NASDAQ:SLDB) is a biotechnology company developing genetic medicines for neuromuscular and cardiac diseases. The company combines gene therapy, genetic medicine and manufacturing technologies to design treatments intended to address the underlying causes of serious inherited disorders. Solid’s lead program is SGT-003, an investigational gene therapy being developed for Duchenne muscular dystrophy, a progressive genetic disease that causes muscle degeneration. The company is also advancing SGT-501, an investigational gene therapy for BAG3-associated dilated cardiomyopathy, a rare inherited heart condition. These products remain in clinical development and are not approved for commercial use. Founded in 2013, Solid Biosciences initially focused primarily on Duchenne muscular dystrophy and has since expanded its research into additional neuromuscular and cardiac conditions. The company broadened its gene therapy capabilities through the acquisition of AavantiBio in 2022. Solid is headquartered in Cambridge, Massachusetts, and conducts research and clinical development activities primarily in the United States and through international clinical collaborations. Bo Cumbo serves as the company’s president and chief executive officer.View Solid Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
